If you've been living with a PCOS diagnosis (or have been trying to get one) you may have just seen this news making the rounds: PCOS has officially been renamed.
As of May 12, 2026, polycystic ovary syndrome is now called polyendocrine metabolic ovarian syndrome, or PMOS. The change was published in The Lancet following one of the most extensive disease-renaming processes in medical history! Over a decade of work, 22,000 survey responses and input from 56 leading academic, clinical, and patient organizations worldwide.
So what changed? And what does it mean for you?
The Old Name Was a Bit of a Lie
Here's the thing about "polycystic ovary syndrome": it was always a misnomer. The name implied that the defining feature of the condition was cysts on the ovaries. It's not. What shows up on ultrasound are arrested follicles, not pathological cysts and cysts aren't even required for a diagnosis.
The name was misleading from the start and the research shows it caused real harm. Studies suggest that up to 70% of people with the condition go undiagnosed and the mislabeling has long been cited as a reason why. When the name points to the wrong thing, doctors can miss the bigger picture, patients get sent in circles and treatment gets delayed.
What Does PMOS Mean?
Polyendocrine — recognizes that the condition involves multiple interacting hormonal disturbances, not just the ovaries. Insulin signaling, androgens and neuroendocrine pathways are all part of the picture.
Metabolic — acknowledges what the research has been pointing to for years: PMOS comes with real metabolic implications, including insulin resistance, increased risk of type 2 diabetes and elevated cardiovascular risk.
Ovarian — the ovaries are still part of the story (just not the whole story).
This matters because the old framing kept PMOS trapped inside a gynecological box when it's really a full-body, multisystem condition. By leading with hormones and metabolism, the new name better reflects what people with this condition actually experience day to day.
What Hasn't Changed
If you were diagnosed with PCOS, that diagnosis still stands! It's the same condition, now with a more accurate name.
The diagnostic criteria remain largely the same for now. Clinicians still use what's called the Rotterdam criteria, which requires meeting at least two of three features: irregular or absent ovulation, signs of elevated androgens (like acne, excess hair growth, or elevated testosterone on bloodwork), and ovarian morphology (follicles that look like cysts) on ultrasound. Updated clinical guidelines are expected to follow the name change over the coming years.
Medications, treatment protocols and management strategies haven't changed yet either. The renaming is the beginning of a shift, not an overnight overhaul.
Why This Matters
Naming things correctly changes how they're treated by the medical system, researchers, insurers and the people living with them.
For too long, PMOS was understood as a fertility problem. The reality is that it affects weight, metabolic health, mental health, skin, the cardiovascular system and more. When the name reduces all of that to "cysts on ovaries," it shapes how much research gets funded, how seriously the condition is taken in clinical settings and how quickly people get the help they need.
The renaming sets the foundation for something more: better medical education, updated global disease classifications and a broader understanding that this condition deserves real, coordinated care.
If you've been dealing with symptoms but haven't had answers yet? Read this post about How to Know If You Have PMOS.
Sources: The Lancet (May 12, 2026); Endocrine Society; Contemporary OB/GYN; AJMC